About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
JAZZ - Jazz Pharmaceuticals...| Previous Close | $148.93 | Open | $148.29 |
| Volume | 27.9K | Market Cap | 8.333B |
| Yield | Last Dividend |
| Exosome Therapeutic Market (COVID-19 Imp... | 8:11 AM |
| This Exosome Therapeutic Market research report makes available state-of-the-art information about the entire market along with the holistic view of t... | |
| Jazz Pharmaceuticals Picks Up SpringWork... | 10/26/20 |
| Jazz Pharmaceuticals plc (NASDAQ: JAZZ ) is set to buy assets from SpringWorks Therapeutics Inc. (NASDAQ: SWTX ) for an upfront payment of $35 million... | |
| Jazz Pharmaceuticals Acquires SpringWork... | 10/26/20 |
| DUBLIN and STAMFORD, Conn., Oct. 26, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and SpringWorks Therapeutics, Inc. (Nasdaq: SWTX) ("... | |
| FY2020 EPS Estimates for Jazz Pharmaceut... | 10/23/20 |
| Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) ??? Research analysts at SVB Leerink increased their FY2020 EPS estimates for shares of Jazz Pharmaceuticals in... | |
| Global Psychedelic Drugs Market 2020 to ... | 10/23/20 |
| The Global Psychedelic Drugs Market report clearly explains what market definition, classifications, applications, engagements and market trends are f... | |
| Psychedelic Drugs Market Size, Share, Gr... | 10/23/20 |
| DBMR has added a new report titled Psychedelic Drugs Market with data Tables for historical and forecast years represented with Chats & Graphs spread ... | |
| Jazz returns to Wakefield | 10/22/20 |
| Wakefield Jazz Club???s resumed programme is set to continue this week. | |
| FY2020 EPS Estimates for Jazz Pharmaceut... | 10/22/20 |
| Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) ??? Analysts at SVB Leerink increased their FY2020 earnings per share (EPS) estimates for Jazz Pharmaceuticals ... | |
| 'A tool for systemic change': jazz comes... | 10/22/20 |
| Ronnie Scott???s plays host to musical luminaries for a one-off programme highlighting the continued power of music by Nina Simone, Billie Holiday and... | |
| Truist Increases Jazz Pharmaceuticals (N... | 10/22/20 |
| Jazz Pharmaceuticals (NASDAQ:JAZZ) had its price target hoisted by equities research analysts at Truist from $157.00 to $175.00 in a report released o... | |
| Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock... | 10/22/20 |
| Jazz Pharmaceuticals (NASDAQ:JAZZ) was downgraded by BidaskClub from a ???buy??? rating to a ???hold??? rating in a research report issued on Tuesday,... | |
| Zacks: Brokerages Anticipate Jazz Pharma... | 10/21/20 |
| Wall Street analysts expect Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) to announce $4.03 earnings per share (EPS) for the current fiscal quarter, accordin... | |
| Jazz Pharmaceuticals (NASDAQ:JAZZ) Downg... | 10/21/20 |
| BidaskClub lowered shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) from a buy rating to a hold rating in a research report sent to investors on Tuesday m... | |
| Jazz Pharmaceuticals (NASDAQ:JAZZ) Price... | 10/20/20 |
| Jazz Pharmaceuticals (NASDAQ:JAZZ) had its price objective boosted by Truist from $157.00 to $175.00 in a report released on Tuesday morning, The Fly ... | |
| Jazz Pharmaceuticals (NASDAQ:JAZZ) Price... | 10/20/20 |
| Jazz Pharmaceuticals (NASDAQ:JAZZ) had its price target upped by stock analysts at Truist from $157.00 to $175.00 in a research note issued on Tuesday... | |
| Jazz Pharmaceuticals Announces SLEEP Pub... | 10/20/20 |
| DUBLIN, Oct. 20, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the publication of the global Phase 3 double-blind, plac... | |
| Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) E... | 10/19/20 |
| Wall Street analysts expect Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) to announce $573.85 million in sales for the current fiscal quarter, according to Z... | |
| Short Interest in Jazz Pharmaceuticals P... | 10/19/20 |
| Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) was the target of a significant growth in short interest in the month of September. As of September 30th, there... | |
| The Active Pharmaceutical Ingredients Ma... | 10/19/20 |
| LONDON--(BUSINESS WIRE)-- #ActivePharmaceuticalIngredientsMarket--The Global Active Pharmaceutical Ingredients Market will grow by $ 60.56 bn during 2... | |
| Jazz Pharmaceuticals to Report 2020 Thir... | 10/19/20 |
| DUBLIN, Oct. 19, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2020 third quarter financial res... | |
| Global Exosome Therapeutic Market Outloo... | 10/19/20 |
| A DBMR team makes use of simple language and easy to understand statistical images to provide thorough information and in-depth data on the industry a... | |
| U.S. Psychedelic Drugs Market 2020 Indep... | 10/19/20 |
| Key players in the market, major collaborations, merger and acquisitions along with trending innovation and business policies are reviewed in this per... | |
| Narcolepsy Drug Market to See Huge Growt... | 10/19/20 |
| The global analysis of Narcolepsy Drug Market and its upcoming prospects have recently added by HealthCare Intelligence Markets to its extensive repos... | |
| New Data for Zepzelca??? (lurbinectedin)... | 10/14/20 |
| DUBLIN, Oct. 14, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and its partner PharmaMar (MSE: PHM) today announced they will present n... | |
| Jazz Pharmaceuticals: Long-Term Prospect... | 10/14/20 |
| Despite the groundbreaking announcements in the recent past, JAZZ???s YTD performance lags the broader market. | |
| Exosome therapeutic Market Next Big Thin... | 10/13/20 |
| Data Bridge Market Research has recently added a concise research on the Exosome Therapeutic Market - Industry Trends and Forecast to 2026. Exosome Th... | |
| The Daily Biotech Pulse: J&J Pauses Coro... | 10/13/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 12) 10X... | |
| COVID-19 UPDATE: Psychedelic Drugs Marke... | 10/12/20 |
| Data Bridge Market Research has recently added a concise research on the Psychedelic Drugs Market to depict valuable insights related to significant m... | |
| IPO Outlook: Solar Power Company Array T... | 10/11/20 |
| This week could see up to nine companies price their IPOs. Here is a look at the companies looking to go public this week. Codiak Biosciences: Clinica... | |
| U.S. Psychedelic Drugs Market is Expecte... | 10/09/20 |
| U.S. Psychedelic Drugs Market report endows with an examination of a range of segments that are relied upon to witness the quickest development amid t... | |
| Buy rating | 10/09/20 |
| HC Wainwright & Co. maintains Buy rating and raises Price Target from $175.00 to $185.00 | |
| Strong Buy rating | 10/09/20 |
| SVB Leerink maintains Outperform rating and raises Price Target from $164.00 to $182.00 | |
| Buy rating | 10/09/20 |
| Jefferies maintains Buy rating and raises Price Target from $151.00 to $188.00 | |
| Sell rating | 09/14/20 |
| Goldman Sachs downgrades from Neutral to Sell rating and announces Price Target of $128.00 | |
| Strong Buy rating | 08/13/20 |
| Wells Fargo maintains Overweight rating and raises Price Target from $150.00 to $171.00 | |
| Date | 2020-08-04 (AMC) | Est. (EPS/Rev.) | $3.11/ 504.65M |
| Actual (EPS/Rev.) | $3.71/ $562.44 M | EPS (TTM) | 0 |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Service Name | Trader | % Success | |
|---|---|---|---|
| smashingdon | Paul | 63.00 % | Follow |
| TopFlight Trades - Premium (Options) | Eric Cunningham | 51.00 % | Follow |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
